• head_banner_01

Manufactur standard N Acetyl Tyrosine Dosage - Semaglutide for Type 2 Diabetes – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We have now sophisticated machines. Our solutions are exported to the USA, the UK and so on, enjoying a great reputation amid consumers for 4′-Trifluoromethyl-Biphenyl-4-Carbaldehyde, Chromium 3 Acetate, Acetate De Zinc, Let's cooperate hand in hand to jointly make a beautiful future. We sincerely welcome you to visit our company or contact us for cooperation!
Manufactur standard N Acetyl Tyrosine Dosage - Semaglutide for Type 2 Diabetes – Gentolex Detail:

Product Detail

Name  Semaglutide
CAS number  910463-68-2
Molecular formula  C187H291N45O59
Molecular weight  4113.57754
EINECS Number  203-405-2

Synonyms

Sermaglutide; Semaglutide fandachem; Semaglutide impurity; Sermaglutide USP/EP; semaglutide; Sermaglutide CAS 910463 68 2; Ozempic, 

Description

Semaglutide is a new generation of GLP-1 (glucagon-like peptide-1) analogs, and semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which has a better effect in the treatment of type 2 diabetes. Novo Nordisk has completed 6 Phase IIIa studies of semaglutide injection, and submitted a new drug registration application for semaglutide weekly injection to the U.S. Food and Drug Administration (FDA) on December 5, 2016. A Marketing Authorization Application (MAA) was also submitted to the European Medicines Agency (EMA).

Compared with liraglutide, semaglutide has a longer aliphatic chain and increased hydrophobicity, but semaglutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced. After PEG modification, it can not only bind closely to albumin, cover the enzymatic hydrolysis site of DPP-4, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.

Application

Semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which is more effective in treating type 2 diabetes.

Bioactivity

Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC0113-0217) is a long-acting glucagon-like peptide 1 (GLP-1) analog, an agonist of GLP-1receptor, with a potential type 2 Therapeutic efficacy of diabetes mellitus (T2DM).

Quality System

In general, quality system and assurance is in place covering all stage of production of the finished product. Adequate manufacturing and control operations are performed in compliance with the approved procedures/ specifications. Change control and Deviation handling system is in place, and necessary impact assessment and investigation were conducted. Proper procedures are in place to ensure quality of product prior to release into the market.


Product detail pictures:

Manufactur standard N Acetyl Tyrosine Dosage - Semaglutide for Type 2 Diabetes – Gentolex detail pictures

Manufactur standard N Acetyl Tyrosine Dosage - Semaglutide for Type 2 Diabetes – Gentolex detail pictures


Related Product Guide:

We emphasize enhancement and introduce new solutions into the market just about every year for Manufactur standard N Acetyl Tyrosine Dosage - Semaglutide for Type 2 Diabetes – Gentolex , The product will supply to all over the world, such as: Italy, London, Denmark, Welcome to visit our company, factory and our showroom where displays various hair products that will meet your expectation. Meanwhile, it is convenient to visit our website, and our sales staff will try their best to provide you the best service. Please contact us if you need more information. Our aim is to help customers realize their goals. We are making great efforts to achieve this win-win situation.
  • The enterprise has a strong capital and competitive power, product is sufficient, reliable, so we have no worries on cooperating with them.
    5 Stars By Freda from Pretoria - 2018.07.27 12:26
    It is really lucky to meet such a good supplier, this is our most satisfied cooperation, I think we will work again!
    5 Stars By Denise from Cyprus - 2017.07.07 13:00
    Write your message here and send it to us